Nicotinamide mononucleotide (NMN), a precursor to the vital cellular cofactor NAD+, is gaining strong human data as a potential ally against age-related decline in muscle and liver health.
NAD+ (nicotinamide adenine dinucleotide) is essential for energy production, DNA repair, and the activity of longevity-related enzymes called sirtuins. NAD+ levels naturally decline with age, and this drop has been linked to reduced mitochondrial function, increased inflammation, and metabolic dysfunction in multiple tissues.
NMN is a direct NAD+ precursor that can raise NAD+ levels when taken orally, as shown in numerous animal and early human studies. By restoring NAD+ availability, NMN may help support healthier metabolism, better energy handling, and improved cellular repair in organs such as muscle and liver.
New Multi-Study Evidence: Muscle Benefits
A recent meta-analysis from Wuhan University pooled data from 13 randomised controlled trials (9 independent studies) involving 412 middle-aged and older adults from Japan, China, and the United States. Participants took between 250 and 1250 mg of NMN daily for 4–24 weeks, allowing researchers to assess real-world dosing and duration.
In eight trials that measured gait speed, a key marker of mobility and functional aging, NMN supplementation increased walking speed by roughly 1 ft/s on average, although individual responses varied. Gains were notably larger in participants under 60, suggesting that earlier intervention may yield greater muscle-performance benefits.
Interestingly, grip strength, another common muscle measure, showed little change overall, with some improvement only in adults over 60. This pattern suggests that NMN may preferentially enhance dynamic performance (like walking) rather than raw strength, at least over short- to medium-term supplementation.
Liver Health and Metabolic Effects
The same meta-analysis examined standard markers of liver function, AST (aspartate aminotransferase) and ALT (alanine aminotransferase), across six clinical trials. While NMN did not significantly alter AST, it did significantly reduce ALT levels, particularly when taken for less than 10 weeks or in participants under 60.
Elevated ALT is often a sign of liver strain or injury, so reductions may indicate improved liver resilience or lower underlying inflammation. The analysis also found that lower doses of NMN had the strongest effect on insulin resistance (measured by HOMA-IR), hinting that modest, sustained dosing could support metabolic health without requiring high intakes.
However, not all trials were uniformly positive. A Harvard-led RCT using a higher dose (2 grams per day) in overweight and obese adults did not find improvements in liver enzymes, insulin resistance, or muscle strength measures such as stair climbing. This contrast supports the idea that dose, duration, and participant characteristics matter greatly when evaluating NMN’s benefits.
Safety, Limitations, and Practical Takeaways
Across the pooled trials, NMN was generally well tolerated, with no serious adverse events reported, supporting its reputation as a safe supplement for middle-aged and older adults. Researchers concluded that NMN shows “positive efficacy” in enhancing muscle function, reducing insulin resistance, and lowering liver aminotransferase levels, calling it an “encouraging and considerable” candidate for anti-aging treatment.
At the same time, the authors emphasised that the existing studies are relatively small, short in duration, and variable in quality, making larger, multi-center RCTs essential before firm clinical recommendations can be made. NMN should be viewed as a promising adjunct, ideally combined with exercise, a balanced diet, and good sleep, rather than a standalone solution.
For individuals considering NMN, sensible steps include:
References
